ReviewProtein science : a publication of the Protein Society2017
Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy.
Review in Protein science : a publication of the Protein Society, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
29 citing papers in PubMed, 58 citations in OpenAlex.
- Exploring the Role of Azurin from the Endophytic BacteriumMicroorganisms · 2026Article
- Possible Applications of Azurin, a Copper-Containing Protein, in Cancer Treatment: Prospects and Challenges.Current drug targets · 2026Review
- A bacterial toxin as a novel anti-cancer drug modulating the tumor-microenvironment.Cell death & disease · 2025Article
- HapA protease targets PAR-1/2 to modulate ERK signalling and reduce cancer cell viability.Cell death discovery · 2025Article
- Genetic mutations enhance the production of Exotoxin A byExperimental and therapeutic medicine · 2025Article
- Inhibition of 53BP1-mediated DNA damage repair by a bacterial effector protein.Fundamental research · 2025Article
- The Production of Recombinant Azurin fromInternational journal of molecular sciences · 2025Article
- Combination of magnetic hyperthermia and gene therapy for breast cancer.Apoptosis : an international journal on programmed cell death · 2025Article
- Azurin a potent anticancer and antimicrobial agent isolated from a novel Pseudomonas aeruginosa strain.Scientific reports · 2025Article
- Design and computational analysis of a novel Azurin-BR2 chimeric protein against breast cancer.Toxicology research · 2024Article
- Heterologous Expression of Codon-Optimized Azurin Transferred by Magnetofection Method in MCF-10A Cells.Molecular biotechnology · 2024Article
- Sonogenetics-controlled synthetic designer cells for cancer therapy in tumor mouse models.Cell reports. Medicine · 2024Article
- Anticancer peptides as novel immunomodulatory therapeutic candidates for cancer treatment.Exploration of targeted anti-tumor therapy · 2024Review
- Review
- Cross-talk between cancer and Pseudomonas aeruginosa mediates tumor suppression.Communications biology · 2023Article
- Review
- Do Bacteria Provide an Alternative to Cancer Treatment and What Role Does Lactic Acid Bacteria Play?Microorganisms · 2022Review
- Bacteria-Mediated Modulatory Strategies for Colorectal Cancer Treatment.Biomedicines · 2022Review
- Extracellular production of azurin from Pseudomonas aeruginosa in the presence of Triton X-100 or Tween 80.Bioprocess and biosystems engineering · 2022Article
- The Azurin Coding Gene: Origin and Phylogenetic Distribution.Microorganisms · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Azurin secreted by Pseudomonas aeruginosa is an anticancer bacteriocin, which preferentially enters human cancer cells and induces apoptosis or growth inhibition. It turns out that azurin is a multi-target anticancer agent interfering in the p53 signaling pathway and the non-receptor tyrosine kinases signaling pathway. This suggests that azurin exerts its anticancer activity by interacting with multiple targets and interfering in multiple steps in disease progression. Therefore, azurin could overcome resistance to therapy. Besides azurin, putative bacteriocins that possess functional properties similar to those of azurin have been identified in more bacteria species. A systematic investigation on the anticancer mechanisms of azurin and the azurin-like bacteriocins will provide more and better options in cancer therapy. In this review, we summarize how azurin and the derived peptides hijack key cellular regulators or cell surface receptors to remodel the cellular signaling networks. In particular, we highlight the necessity of determining the structure of azurin/p53 complex and investigating the influence of post-translational modifications on interactions between azurin and p53. Therapeutic applications of azurin and derived peptides are also discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.